Terms: = Prostate cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 AND Prognosis
35 results:
1. Tyrosine phosphatase
Chen X; Keller SJ; Hafner P; Alrawashdeh AY; Avery TY; Norona J; Zhou J; Ruess DA
Front Immunol; 2024; 15():1340726. PubMed ID: 38504984
[TBL] [Abstract] [Full Text] [Related]
2. Network pharmacology and experimental evaluation strategies to decipher the underlying pharmacological mechanism of Traditional Chinese Medicine CFF-1 against prostate cancer.
Wei Y; Zhu M; Chen Y; Ji Q; Wang J; Shen L; Yang X; Hu H; Zhou X; Zhu Q
Aging (Albany NY); 2024 Mar; 16(6):5387-5411. PubMed ID: 38484140
[TBL] [Abstract] [Full Text] [Related]
3. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
4. Comprehensive analysis of integrin αvβ3/α6β1 in prognosis and immune escape of prostate cancer.
Liu Y; He JX; Ji B; Wang JF; Zhang L; Pang ZQ; Wang JS; Ding BC; Ren MH
Aging (Albany NY); 2023 Oct; 15(20):11369-11388. PubMed ID: 37862114
[TBL] [Abstract] [Full Text] [Related]
5. The prognosis-Predictive and Immunoregulatory Role of SUMOylation Related Genes: Potential Novel Targets in prostate cancer Treatment.
Sun JX; An Y; Xiang JC; Xu JZ; Hu J; Wang SG; Xia QD
Int J Mol Sci; 2023 Sep; 24(17):. PubMed ID: 37686409
[TBL] [Abstract] [Full Text] [Related]
6. Integrative exploration of the mutual gene signatures and immune microenvironment between benign prostate hyperplasia and castration-resistant prostate cancer.
Wu F; Ning H; Sun Y; Wu H; Lyu J
Aging Male; 2023 Dec; 26(1):2183947. PubMed ID: 36974949
[TBL] [Abstract] [Full Text] [Related]
7. Reversal of Lactate and pd-1-mediated Macrophage Immunosuppression Controls Growth of PTEN/p53-deficient prostate cancer.
Chaudagar K; Hieromnimon HM; Khurana R; Labadie B; Hirz T; Mei S; Hasan R; Shafran J; Kelley A; Apostolov E; Al-Eryani G; Harvey K; Rameshbabu S; Loyd M; Bynoe K; Drovetsky C; Solanki A; Markiewicz E; Zamora M; Fan X; Schürer S; Swarbrick A; Sykes DB; Patnaik A
Clin Cancer Res; 2023 May; 29(10):1952-1968. PubMed ID: 36862086
[TBL] [Abstract] [Full Text] [Related]
8. The Oncogenic and Immunological Roles of Apoptosis Antagonistic Transcription Factors in Human Tumors: A Pan-cancer Analysis.
Lu F; Wu J; Zou H; Yang X; Wu Y; Xu J
Oxid Med Cell Longev; 2022; 2022():3355365. PubMed ID: 36275893
[TBL] [Abstract] [Full Text] [Related]
9. The association between PI3K, JAK/STAT pathways with the PDL-1 expression in prostate cancer.
Kazan O; Kir G; Culpan M; Cecikoglu GE; Atis G; Yildirim A
Andrologia; 2022 Nov; 54(10):e14541. PubMed ID: 35880672
[TBL] [Abstract] [Full Text] [Related]
10. Molecular Landscape of LncRNAs in prostate cancer: A focus on pathways and therapeutic targets for intervention.
Mirzaei S; Paskeh MDA; Okina E; Gholami MH; Hushmandi K; Hashemi M; Kalu A; Zarrabi A; Nabavi N; Rabiee N; Sharifi E; Karimi-Maleh H; Ashrafizadeh M; Kumar AP; Wang Y
J Exp Clin Cancer Res; 2022 Jul; 41(1):214. PubMed ID: 35773731
[TBL] [Abstract] [Full Text] [Related]
11. Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to pd-1 axis blockers in non-small cell lung cancer.
Lopez de Rodas M; Nagineni V; Ravi A; Datar IJ; Mino-Kenudson M; Corredor G; Barrera C; Behlman L; Rimm DL; Herbst RS; Madabhushi A; Riess JW; Velcheti V; Hellmann MD; Gainor J; Schalper KA
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35649657
[TBL] [Abstract] [Full Text] [Related]
12. Antibody-Drug Conjugates in Uro-Oncology.
Sigorski D; Różanowski P; Iżycka-Świeszewska E; Wiktorska K
Target Oncol; 2022 May; 17(3):203-221. PubMed ID: 35567672
[TBL] [Abstract] [Full Text] [Related]
13. Characterization of a Pyroptosis-Related Signature for prognosis Prediction and Immune Microenvironment Infiltration in prostate cancer.
Zhang G; Luo Y; Dong W; Zhong W
Comput Math Methods Med; 2022; 2022():8233840. PubMed ID: 35516457
[TBL] [Abstract] [Full Text] [Related]
14. A high homologous recombination deficiency score is associated with poor survival and a non-inflamed tumor microenvironment in head and neck squamous cell carcinoma patients.
Chen Y; Zheng X; Lin J; Gao X; Xiong J; Liu J; Fei Z; Chen C
Oral Oncol; 2022 May; 128():105860. PubMed ID: 35428026
[TBL] [Abstract] [Full Text] [Related]
15. Exploration of Redox-Related Molecular Patterns and the Redox Score for prostate cancer.
Wu Y; Zhang X; Feng H; Hu B; Deng Z; Wang C; Liu B; Luan Y; Ruan Y; Liu X; Liu Z; Liu J; Wang T
Oxid Med Cell Longev; 2021; 2021():4548594. PubMed ID: 34804366
[TBL] [Abstract] [Full Text] [Related]
16. A novel immune-related gene-based prognostic signature to predict biochemical recurrence in patients with prostate cancer after radical prostatectomy.
Lv D; Wu X; Chen X; Yang S; Chen W; Wang M; Liu Y; Gu D; Zeng G
Cancer Immunol Immunother; 2021 Dec; 70(12):3587-3602. PubMed ID: 33934205
[TBL] [Abstract] [Full Text] [Related]
17. The roles of pd-1/PD-L1 in the prognosis and immunotherapy of prostate cancer.
Xu Y; Song G; Xie S; Jiang W; Chen X; Chu M; Hu X; Wang ZW
Mol Ther; 2021 Jun; 29(6):1958-1969. PubMed ID: 33932597
[TBL] [Abstract] [Full Text] [Related]
18. Cell membrane and nuclear expression of programmed death ligand-1 in prostate needle biopsy tissue in prostate cancer patients undergoing primary radiation therapy.
Shim KH; Kwon JE; Park SG; Choo SH; Kim SJ; Kim SI
Urol Oncol; 2021 May; 39(5):298.e13-298.e20. PubMed ID: 33712343
[TBL] [Abstract] [Full Text] [Related]
19. The efficacy of pd-1/PD-L1 blockade in cold cancers and future perspectives.
Majidpoor J; Mortezaee K
Clin Immunol; 2021 May; 226():108707. PubMed ID: 33662590
[TBL] [Abstract] [Full Text] [Related]
20. Treatment-emergent neuroendocrine prostate cancer with a germline
Pandya D; Shah M; Kaplan F; Martino C; Levy G; Kazanjian M; Batter S; Martignetti J; Frank RC
Cold Spring Harb Mol Case Stud; 2021 Feb; 7(1):. PubMed ID: 33608381
[TBL] [Abstract] [Full Text] [Related]
[Next]
